AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

SELLAS Life Sciences Group, Inc. Director's Dealing 2013

Mar 2, 2013

33651_dirs_2013-03-01_f4c1238f-e07d-443d-b347-4843017278c6.zip

Director's Dealing

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: RXi Pharmaceuticals Corp (RXII)
CIK: 0001533040
Period of Report: 2013-03-01

Reporting Person: Galena Biopharma, Inc. (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common stock, $0.0001 par value	33476595	Direct